Introduction
Complicated urinary tract infections (cUTIs) are a major cause of hospital admissions and are the most frequent cause of nosocomial infections. They are also associated with significant morbidity and increased healthcare costs (1) . Resistance to first-line antimicrobials, such as fluoroquinolones, cotrimoxazole, and oral cephalosporins, among urinary Escherichia coli and Klebsiella isolates limits the therapeutic options in some geographic regions, including Turkey. Carbapenems and betalactam/ betalactamase inhibitor combinations remain the drugs of choice for the treatment of severe infections due to extended spectrum beta-lactamase (ESBL)producing Enterobacteriaceae (1, 2) . Few studies have evaluated the comparative activity of carbapenems and beta-lactam/ beta-lactamase inhibitor combinations.
In this study, we aimed to compare the activity of ertapenem and piperacillintazobactam for the treatment of cUTIs due to ESBL-producing E. coli and Klebsiella spp.
We also analyzed the risk factors for the development of a superinfection during treatment.
urinary tract infections, prior antibiotic use, diabetes mellitus, urological interventions, and nephrolithiasis were accepted as markers of a cUTI (3) . Patients less than 18 years of age and patients who were treated with antibiotics other than ertapenem and piperacillin-tazobactam were excluded from the study.
The microbiological response of each patient was evaluated after 48 h of treatment, and then once again (median: 5th day) during the treatment. Microbiological responses were defined as follows: eradication (uropathogen ≥10 5 cfu/mL at entry reduced to <10 4 cfu/ mL); persistence (urine culture grew ≥10 4 cfu/mL of an initial uropathogen); and superinfection (urine culture during therapy grew ≥10 5 cfu/mL of a pathogen other than the initial pathogen) (4) . Treatment responses (eradication, persistence, and superinfection), outcomes, and the risk factors for cUTI in both the ertapenem and piperacillin-tazobactam groups were compared using SPSS 15.0 (SPSS Inc., Chicago, IL, USA). The risk factors affecting the development of a superinfection were also analyzed. Continuous variables are presented as mean ± standard deviation and median (minimum, maximum), while categorical variables are given as a number and percentage. Continuous variables were compared with the Mann-Whitney U test and categorical variables with the chisquare test. P < 0.05 was considered significant.
Logistic regression (LR) models were built to determine the risk factors of a superinfection (last step was presented, method: backward LR, entry: 0.05, removal: 0.10). The LR model of superinfections under treatment included urinary catheterizations, nephrolithiasis, diabetes mellitus, urological interventions, immunosuppression, recurrent urinary tract infections, and antibiotic treatment within the last 3 months. The LR model for the risk factors of an enterococcal superinfection in the ertapenem group included urinary catheterizations, nephrolithiasis, diabetes mellitus, urological interventions, urinary malignancies, recurrent urinary tract infections, and antibiotic treatment within the last 3 months.
Results
A total of 230 patients were enrolled in this study. Of these, 170 received ertapenem and 60 received piperacillintazobactam. The distribution of the patients' descriptive characteristics is presented in Table 1 . The frequency of malignancy, history of recurrent urinary tract infections, and the presence of antibiotic treatment within the last 3 months were significantly different between the ertapenem and piperacillintazobactam treatment groups (P < 0.05).
In both groups, urine cultures after 48 h were negative for the initial uropathogens. However, the frequency of superinfections was 29.4% in the ertapenem group and 8.3% in the piperacillin-tazobactam group over the duration of the treatment. This difference between groups was statistically significant (P < 0.05). The frequency of superinfection in both groups is shown in Table 2 .
Thirty-five patients developed a superinfection in the ertapenem group; at the 48-h urine culture, the isolated microorganisms included Enterococcus spp. (n = 25), Pseudomonas spp. (n = 4), Candida spp. (n = 4), and S. maltophilia (n = 2). In the piperacillin-tazobactam group, only five patients had superinfections and all of these were due to Candida spp.
Urine cultures after the 48th hour of treatment were positive in 22 patients in the ertapenem group and in one patient in the piperacillin-tazobactam group. The isolated microorganisms included Enterococcus spp. (n = 13), Candida spp. (n = 6), S. maltophilia (n = 2), and Pseudomonas sp. (n = 1) in the ertapenem group and Candida sp. (n = 1) in the piperacillin-tazobactam group. Of seven patients in the ertapenem group and one patient in the piperacillin-tazobactam group, urine cultures grew different microorganism at the 48th and after the 48th hour.
Superinfection risk factors for the total duration of treatment were analyzed using the LR model. Urinary catheterization increased the superinfection risk 2.88-fold (CI: 1.44-5.76) in the ertapenem group (P < 0.05), and diabetes mellitus increased the risk 8.50-fold (CI: 1.16-62.09) fold in the piperacillin-tazobactam group (P < 0.05).
The main pathogen isolated from superinfections in the ertapenem group after 48 h was Enterococcus spp. (71.4%). When the risk factors for an enterococcal superinfection were analyzed, it was found that urinary catheterization and urological intervention were significant risk factors (Table 3) .
In 43 (78.1%) of the 55 patients that developed a superinfection, the initial therapy was changed, or a new antibiotic (teicoplanin, fluconazole, etc.) was added to the therapy. The duration of the treatment was significantly longer in patients with superinfections (14 ± 6.6 days vs. 10 ± 4.2 days, P < 0.001).
Discussion
ESBL production has become more common among E. coli and Klebsiella spp. isolated from urinary tract infections worldwide. Among these isolates, resistance to other classes of antibiotics, such as fluoroquinolones and aminoglycosides, limits the therapeutic options in UTIs. Carbapenems and beta-lactam/beta-lactamase inhibitor combinations are used frequently in the treatment of UTIs caused by ESBL-producing enteric bacteria. Hsueh et al. stated that ESBL production among E. coli isolates in the Asia-Pacific region reached 33%, and nearly half of the isolates were also resistant to quinolones (2) . In this study, carbapenems, including ertapenem, were suggested in the empirical therapy of cUTIs because there is no resistance to these agents. In a Spanish study, ertapenem was very active in vitro against urinary isolates of ESBLproducing Enterobacteriaceae (5) . All of the isolates were susceptible to ertapenem. However, the susceptibility rates to other antimicrobials were low, for instance 15.5% to quinolones, 37.9% to cotrimoxazole, and 77.1% to piperacillintazobactam.
One of the important findings of our study was that both ertapenem and piperacillin-tazobactam were very effective in the treatment of cUTIs caused by ESBLpositive E. coli and Klebsiella spp. Urine cultures obtained at the 48th hour of treatment were negative for the primary pathogen in both treatment groups. Ertapenem, a group 1 carbapenem, seems to be a very good option in the treatment of cUTIs because of its activity against ESBLpositive microorganisms, its elimination by the renal route, and its pharmacokinetic properties, which allow its use as a once-per-day treatment (6) . In the literature, the efficacy of ertapenem in UTI treatments was mostly compared to ceftriaxone. In a prospective, randomized, double-blind, multicenter study, Tomera et al. reported similar microbiological success rates for the ertapenem and ceftriaxone groups (91.8% vs. 93.0%, respectively) (7). In a more recent randomized, double-blind, multicenter study, the efficacies of ertapenem and ceftriaxone were compared in acute pyelonephritis and other cUTIs. A favorable microbiological response was observed in 87.0% and 88.7% of the patients in the ertapenem and ceftriaxone groups, respectively (4).
Piperacillin-tazobactam, a beta-lactam/beta-lactamase inhibitor, is also effective in the treatment of various infections caused by ESBL-positive microorganisms. It is widely used in the treatment of UTIs, lower respiratory tract infections, bloodstream infections, intraabdominal infections, and complicated skin and soft tissue infections (8) . Sifuentes-Osornio et al. suggested that piperacillintazobactam is a reliable therapy in the treatment of cUTIs requiring hospitalization (9) . They reported seeing favorable clinical responses with piperacillin-tazobactam in 83.6% and 80.0% of early and late assessments, respectively. Piperacillin-tazobactam was as effective as imipenem-cilastatin for the treatment of acute complicated pyelonephritis and cUTIs, with 83.0% and 79.9% clinical success, respectively (10) . There were no studies comparing the efficacy of ertapenem and piperacillin-tazobactam in the treatment of cUTIs due to ESBL-producing E. coli and Klebsiella spp. until the current study. Therefore, our study provides valuable data concerning the use of ertapenem and piperacillin-tazobactam for these infections. When we compared ertapenem and piperacillin-tazobactam, both were effective in the treatment of cUTIs, and there was no statistical difference between their activities. However, it seems that ertapenem has some advantages because of both its onceper-day usage and its convenience as an outpatient parenteral antibiotic therapy (11) .
According to our results, the most important finding was the difference in frequency of superinfections between the groups. The frequency of a superinfection was significantly higher in the ertapenem group. We detected a superinfection in one-third of patients in the ertapenem group; however, this rate was only one-tenth in the piperacillintazobactam group. The difference between the two groups was the result of Enterococcus and Pseudomonas spp., against which ertapenem is not active (11) . The LR model revealed that urinary catheterization was an independent risk factor for the development of a superinfection in the ertapenem group, and the presence of diabetes mellitus in the piperacillin-tazobactam group.
In the ertapenem group, Enterococcus spp. was the main pathogen isolated from superinfections and was detected in 71.4% of positive urine cultures after 48 h. Urinary catheterization, diabetes mellitus, and urological intervention were significant risk factors for the development of an enterococcal superinfection. Ertapenem has no activity against Enterococcus spp. or Pseudomonas spp. Therefore, we recommend that ertapenem should be cautiously used in cases where there is a suspicion of Enterococcus and Pseudomonas, especially in patients with urinary catheterization, diabetes mellitus, or urological intervention. Urine cultures should be performed at the 48th hour for the detection of a superinfection.
As a result of superinfection, duration of treatment lengthens; however, this did not cause mortality in our study.. The duration of treatment was significantly longer in patients who had developed a superinfection (P < 0.01).
In conclusion, both ertapenem and piperacillintazobactam were effective in the treatment of cUTIs caused by ESBL-producing enteric gram-negative bacteria. The frequency of superinfections in the ertapenem group was significantly higher than in the piperacillin-tazobactam group. In the presence of urinary catheterization, diabetes mellitus, and urological intervention, patient should be closely monitored for the development of a superinfection, especially patients receiving ertapenem.
